Ixekizumab Gains FDA Approval for Treatment of Active Ankylosing Spondylitis

The FDA has approved Taltz (ixekizumab; Eli Lilly) for the treatment of adults with active ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis.